• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Helfand M, Peterson K, Christensen V, et al. Drug Class Review: Beta Adrenergic Blockers: Final Report Update 4 [Internet]. Portland (OR): Oregon Health & Science University; 2009 Jul.

Appendix D. Excluded studies

The following full-text publications were considered for inclusion but failed to meet the criteria for this report.

Part I. Excluded for Update 4

PublicationReason for Exclusion
Abalos, Duley, Steyn, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy [Systematic Review]. Cochrane Database of Systematic Reviews. 2008;3:3.Wrong study design
Abraham WT, Massie BM, Lukas MA, et al. Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: insights from a large prospective beta-blocker registry. Congestive Heart Failure. Jan–Feb 2007;13(1):16–21.Wrong outcome
Ahrens W, Hagemeier C, Muhlbauer B, et al. Hospitalization rates of generic metoprolol compared with the original beta-blocker in an epidemiological database study. Pharmacoepidemiology & Drug Safety. Dec 2007;16(12):1298–307.Wrong outcome
Aneja P, Srinivas A and Biswas AD. Comparative clinical study of the efficacy and safety of a S-metoprolol ER tablet versus a racemate metoprolol ER tablet in patients with chronic stable angina. International Journal of Clinical Pharmacology & Therapeutics. May 2007;45(5):253–8.Wrong study design
Aursnes I, Osnes J-B, Tvete IF, et al. Does atenolol differ from other beta-adrenergic blockers? BMC Clinical Pharmacology. 2007;7:4.Wrong publication type
Brehm BR, Wolf SC, Gorner S, et al. Effect of nebivolol on left ventricular function in patients with chronic heart failure: a pilot study. European Journal of Heart Failure. Dec 2002;4(6):757–63.Wrong study design
Capucci A, Botto G, Molon G, et al. The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker. American Heart Journal. Aug 2008;156(2):373.e1–8.Wrong study design
Coca A, Messerli FH, Benetos A, et al. Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST. Stroke. Feb 2008;39(2):343–8.Wrong drug
Dahlof B, Devereux RB, Kjeldsen SE, et al. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future? Blood Pressure. 2007;16(1):6–12.Wrong publication type
Dart AM, Cameron JD, Gatzka CD, et al. Similar effects of treatment on central and brachial blood pressures in older hypertensive subjects in the Second Australian National Blood Pressure Trial. Hypertension. Jun 2007;49(6):1242–7.Wrong drug
DasGupta P, Jain D, Lahiri A, et al. Long term efficacy and safety of carvedilol, a new beta-blocking agent with vasodilating properties, in patients with chronic ischaemic heart disease. Drug Invest. 1992;4(3):263–272.Wrong study design
Delea TE, Taneja C, Moynahan A, et al. Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension. American Journal of Health-System Pharmacy. Jun 1 2007;64(11):1187–96.Wrong outcome
Dobre D, Haaijer-Ruskamp FM, Voors AA, et al. beta- Adrenoceptor antagonists in elderly patients with heart failure: a critical review of their efficacy and tolerability. Drugs & Aging. 2007;24(12):1031–44.Wrong publication type
Dungen H-D, Apostolovic S, Inkrot S, et al. Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clinical Research in Cardiology. Sep 2008;97(9):578–86.Wrong publication type
Earl GL, Verbos-Kazanas MA, Fitzpatrick JM, et al. Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone. Pharmacotherapy. May 2007;27(5):697–706.Wrong outcome
Garcia-Monco JC, Foncea N, Bilbao A, et al. Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients. Cephalalgia. Aug 2007;27(8):920–8.Wrong study design
Go AS, Yang J, Gurwitz JH, et al. Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure. American Journal of Cardiology. Aug 15 2007;100(4):690–6.Wrong study design
Kataoka M, Satoh T, Yoshikawa T, et al. Comparison of the effects of carvedilol and metoprolol on exercise ventilatory efficiency in patients with congestive heart failure. Circulation Journal. Mar 2008;72(3):358–63.Wrong outcome
Krum H, Sackner-Bernstein J and al. e. Double-blind, palcebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995;92(6):1499–1506.Wrong study design
Rector TS, Anand IS, Nelson DB, et al. Carvedilol versus controlled-release metoprolol for elderly veterans with heart failure. Journal of the American Geriatrics Society. Jun 2008;56(6):1021–7.Wrong outcome
Rinfret S, Abrahamowicz M, Tu J, et al. A population-based analysis of the class effect of beta-blockers after myocardial infarction. American Heart Journal. Feb 2007;153(2):224–30.Wrong outcome
Taylor FR. Weight change associated with the use of migraine-preventive medications. Clinical Therapeutics. Jun 2008;30(6):1069–80.Wrong publication type
Uhlir O, Dvorak I, Gregor P, et al. Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial. Journal of Cardiac Failure. Dec 1997;3(4):271–6.Wrong study design
Van Bortel LM, Fici F and Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. American Journal of Cardiovascular Drugs. 2008;8(1):35–44.Wrong publication type

Part II. Previously excluded

  1. Agrawal RL. Double-blind comparison of Inderal LA (160 mg), Half-Inderal LA (80 mg), and Half-Inderal LA plus bendrofluazide (2. Br. J. Clin. Pract. 1987;41(9):916–920.
  2. Agrawal RL, Alliott RJ, George M, et al. The treatment of hypertension with propranolol and bendrofluazide. Journal of the Royal College of General Practitioners. 1979;29(207):602–606.
  3. Ahmed A, Dell'Italia LJ. Use of beta-blockers in older adults with chronic heart failure. Am. J. Med. Sci. 2004;328(2):100–111.
  4. Ajayi AA, Sofowora GG, Adigun AQ, Asiyanbola B. Adjunctive sympathoplegic therapy to ACE inhibition in Blacks with congestive heart failure: a comparison of alpha-1 with beta-1 blockade on exercise tolerance and cardiac sympathovagal reflex activity. Ethnicity & Disease. 2003;13(1):71–79.
  5. Akbar A, Pearce MY. Spironolactone and propranolol in the management of hypertension. Br. J. Clin. Pract. 1984;38(3):110–114.
  6. Albers GW, Simon LT, Hamik A, Peroutka SJ. Nifedipine versus propranolol for the initial prophylaxis of migraine. Headache. 1989;29(4):215–218.
  7. Alexandrino PT, Alves MM, Pinto Correia J. Propranolol or endoscopic sclerotherapy in the prevention of recurrence of variceal bleeding. J. Hepatol. 1988;7(2):175–185.
  8. Allen RD, Gettes LS, Phalan C, Avington MD. Painless ST-segment depression in patients with angina pectoris. Correlation with daily activities and cigarette smoking. Chest. 1976;69(4):467–473.
  9. Amsterdam EA, Gorlin R, Wolfson S. Evaluation of long-term use of propranolol in angina pectoris. JAMA. 1969;210(1):103–106.
  10. Andren L, Hansson L, Eggertsen R, Hedner T, Karlberg BE. Circulatory effects of noise. Acta Medica Scandinavica. 1983;213(1):31–35.
  11. Angelico M, Carli L, Piat C, et al. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Gastroenterology. 1993;104(5):1460–1465.
  12. Anonymous. Unstable angina pectoris: National Cooperative Study Group to Compare Medical and Surgical Therapy. IV. Am. J. Cardiol. 1981;48(3):517–524.
  13. Anonymous. Oxprenolol vs propranolol: a randomized, double-blind, multiclinic trial in hypertensive patients taking hydrochlorothiazide. Veterans Administration Cooperative Study Group. Hypertension. 1981;3(2):250–256.
  14. Anonymous. Metoprolol in acute myocardial infarction. Arrhythmias. Other clinical findings and tolerability. Am. J. Cardiol. 1985;56(14):35G-38G.
  15. Anonymous. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. The TIMI Study Group. N. Engl. J. Med. 1989;320(10):618–627.
  16. Anonymous. The total ischemic burden European trial (TIBET): design, methodology, and management. The TIBET Study Group. Cardiovascular Drugs & Therapy. 1992;6(4):379–386.
  17. Anonymous. Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrythmias and on mortality after acute myocardial infarction. Am. J. Cardiol. 1993;72:1234–1238.
  18. Anonymous. Effect of carvedilol on mortality and morbidity in patients with chronic heart failure. Circulation. 1996;94(4):592.
  19. Anonymous. New beta blocker reduces heart failure mortality by two-thirds. Geriatrics. 1996;51(1):16–19.
  20. Anonymous. LIFE study--still-blinded results show promise. Cardiovascular Journal of Southern Africa. 2001;12(2):123–124.
  21. Anonymous. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med. 2001;344(22):1659–1667.
  22. Anonymous. Carvedilol offers women with heart problems the same clinical benefits as men. Cardiovascular Journal of Southern Africa. 2002;13(2):84.
  23. Anonymous. ARB superior to beta blocker in preventing adverse outcomes in older, high-risk hypertensive patients. Geriatrics. 2002;57(5):63–64.
  24. Anonymous. Coreg. Nursing. 2002;32(2):18.
  25. Applegate WB, Phillips HL, Schnaper H, et al. A randomized controlled trial of the effects of three antihypertensive agents on blood pressure control and quality of life in older women. Arch. Intern. Med. 1991;151(9):1817–1823.
  26. Applegate WB, Pressel S, Wittes J, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch. Intern. Med. 1994;154(19):2154–2160.
  27. Aranda JM, Krause-Steinrauf HJ, Greenberg BH, et al. Comparison of the beta blocker bucindolol in younger versus older patients with heart failure. Am. J. Cardiol. 2002;89(11):1322–1326.
  28. Ardissino D, Savonitto S, Egstrup K, et al. Transient myocardial ischemia during daily life in rest and exertional angina pectoris and comparison of effectiveness of metoprolol versus nifedipine. Am. J. Cardiol. 1991;67(11):946–952.
  29. Ardissino D, Savonitto S, Egstrup K, et al. Selection of medical treatment in stable angina pectoris: Results of the International Multicenter Angina Exercise (IMAGE) study. Journal of the American College of Cardiology. 1995;25(7):1516–1521.
  30. Aronow WS. Effect of beta blockers on mortality and morbidity in persons treated for congestive heart failure. J. Am. Geriatr. Soc. 2001;49(3):331–333.
  31. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and diabetes mellitus. Am. J. Cardiol. 2001;87(6):780–781, A788.
  32. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am. J. Cardiol. 1997;80(2):207–209.
  33. Aronow WS, Ahn C, Mercando AD, Epstein S, Kronzon I. Decrease in mortality by propranolol in patients with heart disease and complex ventricular arrhythmias is more an anti-ischemic than an antiarrhythmic effect. Am. J. Cardiol. 1994;74(6):613–615.
  34. Arumanayagam M, Chan S, Tong S, Sanderson JE. Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. J. Cardiovasc. Pharmacol. 2001;37(1):48–54.
  35. Auer J, Weber T, Berent R, et al. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: The Pilot Study of Prevention of Postoperative Atrial Fibrillation (SPPAF), a randomized, placebo-controlled trial. Am. Heart J. 2004;147(4):636–643.
  36. Bai XP, Guo XJ, Zhang LX. Celiprolol vs atenolol in treating hypertension. Chinese Journal of New Drugs and Clinical Remedies. 2001;20(1):43–45.
  37. Bairey CN, Krantz DS, DeQuattro V, Berman DS, Rozanski A. Effect of beta-blockade on low heart rate-related ischemia during mental stress. J. Am. Coll. Cardiol. 1991;17(6):1388–1395.
  38. Balcetyte-Harris N, Tamis JE, Homel P, Menchavez E, Steinberg JS. Randomized study of early intravenous esmolol versus oral beta-blockers in preventing post-CABG atrial fibrillation in high risk patients identified by signal-averaged ECG: Results of a pilot study. Annals of Noninvasive Electrocardiology. 2002;7(2):86–91.
  39. Banares R, Moitinho A, Matilla G, et al. Carvedilol (carv) vs propranolol (prop) in the long-term treatment of portal hypertension (PH) (abstract). J. Hepatol. 2000;32(2).
  40. Barber JM, Murphy FM, Merrett JD. Clinical trial of propranolol in acute myocardial infarction. Ulster Med. J. 1967;36:127–130.
  41. Baxter AJ, Spensley A, Hildreth A, Karimova G, O'Connell JE, Gray CS. Beta blockers in older persons with heart failure: tolerability and impact on quality of life. Heart (British Cardiac Society). 2002;88(6):611–614.
  42. Behan PO, Reid M. Propranolol in the treatment of migraine. Practitioner. 1980;224(1340):201–203.
  43. Beilin LJ, Juel-Jensen BE. Alpha and beta adrenergic blockade in hypertension. Lancet. 1972;1(7758):979–982.
  44. Bekes M, Matos L, Rausch J, Torok E. Treatment of migraine with propranolol. Lancet. 1968;2(7575):980.
  45. Benetos A, Consoli S, Safavian A, Dubanchet A, Safar M. Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. Am. Heart J. 2000;140(4):E11.
  46. Bloem TJJ, Lindner P. Metoprolol in angina pectoris complicated by essential hypertension. A clinical comparison of the antianginal efficacy of metoprolol slow- release tablets (durules(Reg.trademark)) given once daily and propranolol tablets given twice daily. Annals of Clinical Research. 1981;13(Suppl. 30):61–67.
  47. Blumenthal JA, Ekelund LG, Emery CF. Quality of life among hypertensive patients with a diuretic background who are taking atenolol and enalapril. Clinical Pharmacology & Therapeutics. 1990;48(4):447–454.
  48. Boberg J, Larsen FF, Pehrsson SK. The effects of beta blockade with (epanolol) and without (atenolol) intrinsic sympathomimetic activity in stable angina pectoris. The Visacor Study Group. Clin. Cardiol. 1992;15(8):591–595.
  49. Bochkareva EV, Kokurina EV, Metelitsa VI, Pankina VA. Comparative efficacy of proxodolol and propranolol chosen on an individual basis for single and regular use in patients with angina pectoris. Experimental and Clinical Pharmacology. 1994;57(3):51–54.
  50. Boden WE, Bough EW, Reichman MJ, et al. Beneficial effects of high-dose diltiazem in patients with persistent effort angina on beta-blockers and nitrates: a randomized, double-blind, placebo-controlled cross-over study. Circulation. 1985;71(6):1197–1205.
  51. Bohler S, Saubadu S, Scheldewaert R, Figulla HR. Betaxolol versus carvedilol in chronic heart failure (BETACAR study). Arzneimittelforschung. 1999;49(4):311–317.
  52. Boissel JP, Collet JP, Lion L, et al. A randomized comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: field trial in general practice. The OCAPI Study Group. J. Hypertens. 1995;13(9):1059–1067.
  53. Bongers V, Sabin GV. Comparison of the effect of two metoprolol formulations on total ischaemic burden. Clinical Drug Investigation. 1999;17(2):103–110.
  54. Boquist S, Ruotolo G, Hellenius ML, Danell-Toverud K, Karpe F, Hamsten A. Effects of a cardioselective beta-blocker on postprandial triglyceride-rich lipoproteins, low density lipoprotein particle size and glucose-insulin homeostasis in middle-aged men with modestly increased cardiovascular risk. Atherosclerosis. 1998;137(2):391–400.
  55. Bordini CA, Arruda MA, Ciciarelli MC, Speciali JG. Propranolol vs flunarizine vs flunarizine plus propranolol in migraine without aura prophylaxis. Arq. Neuropsiquiatr. 1997;55(3B):536–541.
  56. Borer JS, Comerford MB, Sowton E. Assessment of metoprolol, a cardioselective beta-blocking agent, during chronic therapy in patients with angina pectoris. J. Int. Med. Res. 1976;4(1):15–22.
  57. Borzak S, Fenton T, Glasser SP, et al. Discordance between effects of anti-ischemic therapy on ambulatory ischemia, exercise performance and anginal symptoms in patients with stable angina pectoris. The Angina and Silent Ischemia Study Group (ASIS). J. Am. Coll. Cardiol. 1993;21(7):1605–1611.
  58. Brady AR, Gibbs JSR, Greenhalgh RM, Powell JT, Sydes MR, investigators Pt. Perioperative beta-blockade (POBBLE) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial. J. Vasc. Surg. Apr 2005;41(4):602–609.
  59. Broekman CP, Haensel SM, Van de Ven LL, Slob AK. Bisoprolol and hypertension: effects on sexual functioning in men. Journal of Sex & Marital Therapy. 1992;18(4):325–331.
  60. Browning RC, Ebbutt A, Russell JG, Mayhew SR. A multicentre study of cardioselective metoprolol (Lopresor) and non-selective propranolol in the management of mild to moderate hypertension. Br. J. Clin. Pract. 1981;35(11–12):399–402.
  61. Brunner HR, Waeber B, Ferguson RK, Turini GA, Gavras H. The position of beta-blockers in antihypertensive therapy. Comparison with other antihypertensive agents. Cardiology. 1979;64(1):88–95.
  62. Bugiardini R, Borghi A, Biagetti L, Puddu P. Comparison of verapamil versus propranolol therapy in syndrome X. Am. J. Cardiol. 1989;63(5):286–290.
  63. Bulpitt CJ, Connor M, Schulte M, Fletcher AE. Bisoprolol and nifedipine retard in elderly hypertensive patients: effect on quality of life. J. Hum. Hypertens. 2000;14(3):205–212.
  64. Burri H, Plewan A. Maintainance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation [1] (multiple letters). Eur. Heart J. 2002;23(7):586.
  65. Burroughs AK, Panagou E. Pharmacological therapy for portal hypertension: Rationale and results. Semin. Gastrointest. Dis. 1995;6(3):148–164.
  66. Butzow, G H, Remmecke, J, Brauer, A. Medical treatment of portal hypertension with metoprolol [EASL abstract]. Liver. 1982;2(3 Pt 2).
  67. Cai ZB, Zhen LR. Efficacy evaluation of carvedilol in the treatment of severe congestive heart failure. The Chinese Journal of Modern Applied Pharmacy. 2003;20(1):70–71.
  68. Campo C, Segura J, Fernandez ML, Guerrero L, Christiansen H, Ruilope LM. A prospective comparison of four antihypertensive agents in daily clinical practice. Journal of Clinical Hypertension. 2001;3(3):139–144.
  69. Carey, W E. Variceal hemorrhage--to block or not to block? Am. J. Gastroenterol. 1990;85(6):757–758.
  70. Carroll JD, Reidy M, Savundra PA, Cleave N, McAinsh J. Long-acting propranolol in the prophylaxis of migraine: a comparative study of two doses. Cephalalgia. 1990;10(2):101–105.
  71. Carruthers G, Dessain P, Fodor G, Newman C, Palmer W, Sim D. Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. Am. J. Cardiol. 1993;71(7):575–581.
  72. Castenfors J, Danielsson M. Metoprolol and hydrochlorothiazide in a fixed combination once daily in the treatment of hypertension. Current Therapeutic Research, Clinical & Experimental. 1979;25(2).
  73. Chambers J, Ong ML, Akhras F, Adam G, Jackson G. Effect of partial agonist activity on the side effects of beta-blockade in patients with chronic stable angina. Drugs. 1989;38(Suppl 2):39–44.
  74. Chauhan A, Dardas P, Tirlapur V, Schofield P. A comparison of atenolol with controlled release diltiazem in chronic stable angina. Journal of Clinical Research. 1998;1(357–365):357–365.
  75. Chen BH. Hypertension and alpha-adrenergic blockers: Preliminary ALLHAT results. CMAJ: Canadian Medical Association Journal. 2000;163(4):437.
  76. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1622–1632.
  77. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA. 2003;289(19):2560–2572.
  78. Choong CY, Roubin GS, Harris PJ, et al. A comparison of the effects of beta-blockers with and without intrinsic sympathomimetic activity on hemodynamics and left ventricular function at rest and during exercise in patients with coronary artery disease. J. Cardiovasc. Pharmacol. 1986;8(3):441–448.
  79. Clausen J, Felsby M, Jorgensen FS, Nielsen BL, Roin J, Strange B. Absence of prophylactic effect of propranolol in myocardial infarction. Lancet. 1966;2(7470):920–924.
  80. Cleland JG. Improving patient outcomes in heart failure: evidence and barriers. Heart. 2000;84(Suppl 1):i8–10:discussion i50.
  81. Cleophas TJ, van der Mey N, van der Meulen J, Niemeyer MG. Quality of life before and during antihypertensive treatment: a comparative study of celiprolol and atenolol. International Journal of Clinical Pharmacology & Therapeutics. 1996;34(7):312–317.
  82. Cleophas TJ, van 't Leven M, Kauw FH, Remmert HP, Kuijper A, Zwinderman K. Celiprolol vs propranolol in unstable angina pectoris: a double-blind, randomized, parallel-group study. Angiology. 1995;46(2):137–144.
  83. Cleophas TJ, van 't Leven M, Kauw FH, Remmert HP, Kuijper A, Zwinderman K. Celiprolol and propranolol for unstable angina pectoris. Clinical Pharmacology & Therapeutics. 1995;57(1):67–72.
  84. Cleophas TJ, vd Mey N, Meulen J, Niemeyer MG. Quality of life before and during antihypertensive treatment: a comparative study of celiprolol and atenolol. American Journal of Therapeutics. 1997;4(4):117–122.
  85. Coats AJ. The effects of angiotensin receptor antagonists on mortality and morbidity in heart failure--and an interaction with beta blockade. Int. J. Cardiol. 2001;77(1):1–4.
  86. Cocco G, Strozzi C, Chu D, Amrein R, Castagnoli E. Therapeutic effects of pindolol and nifedipine in patients with stable angina pectoris and asymptomatic resting ischemia. Eur. J Cardiol. 1979;10(1):59–69.
  87. Cohn JN, Tognoni G, Valsartan Heart Failure Trial I. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 2001;345(23):1667–1675.
  88. Comerford MB, Besterman EM. An eighteen months' study of the clinical response to metoprolol, a selective beta1-receptor blocking agent, in patients with angina pectoris. Postgrad. Med. J. 1976;52(610):481–486.
  89. Comerford MB, Besterman EM. A comparison of the effects of the slow release formulations of metoprolol and oxprenolol in hypertension. Annals of Clinical Research. 1982;14(1):27–31.
  90. Connolly SJ, Cybulsky I, Lamy A, et al. Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: The β-Blocker Length Of Stay (BLOS) study. American Heart Journal. 2003;145(2):226–232.
  91. Contreras G, Greene T, Agodoa LY, et al. Blood pressure control, drug therapy, and kidney disease. Hypertension. Jul 2005;46(1):44–50.
  92. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. British Medical Journal Clinical Research Edition. 1986;293(6555):1145–1151.
  93. Cosin AJ, Bayes d LA, Navarro LF. Two year follow-up of Spanish Trial on sudden death. New Trends Arrhythmias. 1992;8(1–2):119–124.
  94. Crea F, Pupita G, Galassi AR, et al. Effects of theophylline, atenolol and their combination on myocardial ischemia in stable angina pectoris. Am. J. Cardiol. 1990;66(17):1157–1162.
  95. Croog SH, Elias MF, Colton T, et al. Effects of antihypertensive medications on quality of life in elderly hypertensive women. Am. J. Hypertens. 1994;7(4 Pt 1):329–339.
  96. Croog SH, Kong BW, Levine S, Weir MR, Baume RM, Saunders E. Hypertensive black men and women. Quality of life and effects of antihypertensive medications. Arch. Intern. Med. 1990;150(8):1733–1741.
  97. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N. Engl. J. Med. 1986;314(26):1657–1664.
  98. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996;276(23):1886–1892.
  99. Cushman WC, Reda DJ, Perry HM, Williams D, Abdellatif M, Materson BJ. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Arch. Intern. Med. 2000;160(6):825–831.
  100. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.
  101. Dahlstrom CG, Edvardsson N, Nasheng C, Olsson SB. Effects of diltiazem, propranolol, and their combination in the control of atrial fibrillation. Clin. Cardiol. 1992;15(4):280–284.
  102. Daly C, Norrie J, Murdoch DL, Ford I, Dargie HJ, Fox K. The value of routine non-invasive tests to predict clinical outcome in stable angina. European Heart Journal. 2003;24(6):532–540.
  103. Dargie HJ, Ford I, Fox KM. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur. Heart J. 1996;17(1):104–112.
  104. Day LJ, Hearon TE, Duncan JT, Sowton E. Pindolol in the treatment of hypertension: a double-blind randomized trial. Practitioner. 1977;219(1314):889–894.
  105. de Bock GH, Eelhart J, van Marwijk HW, Tromp TP, Springer MP. A postmarketing study of flunarizine in migraine and vertigo. Pharm. World Sci. 1997;19(6):269–274.
  106. De Caprio L, Papa M, Acanfora D, et al. Acute effects of nisoldipine, propranolol, and their combination in patients with chronic stable angina: a double-blind, randomized, cross-over, placebo-controlled study. J. Cardiovasc. Pharmacol. 1990;16(2):325–330.
  107. de Hoon JN, Vanmolkot FH, van de Ven LL, Van Bortel LM. Quality of life comparison between bisoprolol and nifedipine retard in hypertension. Cardiovascular Drugs & Therapy. 1997;11(3):465–471.
  108. de Simone G, Wachtell K, Palmieri V, et al. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. Circulation. Apr 19 2005;111(15):1924–1931.
  109. de Soyza N, Murphy ML, Bissett JK, Kane JJ, Doherty JE, 3rd. Ventricular arrhythmias in chronic stable angina pectoris with surgical or medical treatment. Ann. Intern. Med. 1978;89(1):10–14.
  110. de Vries RJ, van den Heuvel AF, Lok DJ, et al. Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. Int. J. Cardiol. 1996;57(2):143–150.
  111. De Vries RJM, Dunselman P, Van Veldhuisen DJ, Van den Heuvel AFM, Wielenga RP, Lie KI. Comparison between felodipine and isosorbide mononitrate as adjunct to beta blockade in patients >65 years of age with angina pectoris. Am. J. Cardiol. 1994;74(12):1201–1206.
  112. Deedwania PC. Sotalol is more powerful than propranolol in suppressing complex ventricular arrhythmias. Journal of Cardiovascular Pharmacology and Therapeutics. 1997;2(4):259–272.
  113. Deedwania PC, Carbajal EV, Nelson JR, Hait H. Anti-ischemic effects of atenolol versus nifedipine in patients with coronary artery disease and ambulatory silent ischemia. J. Am. Coll. Cardiol. 1991;17(4):963–969.
  114. Demers C, McKelvie RS, Negassa A, Yusuf S, Investigators RPS. Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure. Am. Heart J. 2001;142(4):698–703.
  115. Deschenes M, Barkun AN. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. Gastrointest. Endosc. 2000;51(5):630–633.
  116. Di Pasquale P, Paterna S, Bucca V, Licata G. Effects of administration of captopril, metoprolol, and the captopril- metoprolol combination as adjuvant therapy during thrombolysis in acute myocardial infarction [1]. Cardiovascular Drugs & Therapy. 1994;8(6):875–876.
  117. Di Pasquale P, Paterna S, Bucca V, Maringhini G, Magatti M. Effects of the administration of captopril, metoprolol and of the captopril-metoprolol combination as adjuvant therapy during thrombolysis in acute myocardial infarction. International Journal of Cardiology. 1994;46(2):107–112.
  118. Di Somma S, de Divitiis M, Bertocchi F, et al. Treatment of hypertension associated with stable angina pectoris: favourable interaction between new metoprolol formulation (OROS) and nifedipine. Cardiologia. 1996;41(7):635–643.
  119. Di Somma S, Liguori V, Petitto M, et al. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovascular Drugs & Therapy. 1993;7(1):119–123.
  120. Diamond S, Medina JL. Controlled study of prophylaxis of migraine with propranolol. Clinical Pharmacology & Therapeutics. 1975;17(2).
  121. Dickerson LM, Carek PJ. Bisoprolol prevents mortality and myocardial infarction after vascular surgery. J. Fam. Pract. 2000;49(3):203–204.
  122. Diener HC, Hartung E, Chrubasik J, et al. A comparative study of oral acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. Cephalalgia. 2001;21(2):120–128.
  123. Diener HC, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia. 2002;22(3):209–221.
  124. Dimsdale JE, Newton RP. Cognitive effects of beta blockers. J. Psychosom. Res. 1992;36(3):229–236.
  125. Dollet JM, Champigneulle B, Evangelista M, Bigard MA, Gaucher P. Sclerotherapy versus propranolol after first variceal haemorrhage in alcoholic cirrhosis. Lancet. 1985;2(8446):97.
  126. Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur. J. Clin. Pharmacol. 1986;31(2):143–147.
  127. Dotremont G, De Geest H. The use of propranolol (inderal) in acute myocardial infarction. Acta Clin. Belg. 1968;23(3):163–176.
  128. Egstrup K. Randomized double-blind comparison of metoprolol, nifedipine, and their combination in chronic stable angina: effects on total ischemic activity and heart rate at onset of ischemia. Am. Heart J. 1988;116(4):971–978.
  129. Egstrup K, Andersen PE, Jr. Transient myocardial ischemia during nifedipine therapy in stable angina pectoris, and its relation to coronary collateral flow and comparison with metoprolol. Am. J. Cardiol. 1993;71(2):177–183.
  130. Egstrup K, Gundersen T, Harkonen R, Karlsson E, Lundgren B. The antianginal efficacy and tolerability of controlled-release metoprolol once daily: a comparison with conventional metoprolol tablets twice daily. Eur. J. Clin. Pharmacol. 1988;33(Suppl):S45–49.
  131. El Sahly AM, Shendy MS, Abdel Rahman HM. Medical treatment of portal hypertension using verapamil, ketanserin and propranolol alone and in combinations [abstract]. Gut. 1996;39(Suppl 3).
  132. el-Tamimi H, Davies GJ. Optimal control of myocardial ischaemia: the benefit of a fixed combination of atenolol and nifedipine in patients with chronic stable angina. Br Heart J. 1992;68(3):291–295.
  133. Farsang C, Garcia-Puig J, Niegowska J, Baiz AQ, Vrijens F, Bortman G. The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. J. Hypertens. 2000;18(6):795–801.
  134. Ferrucci L, Furberg CD, Penninx BW, et al. Treatment of isolated systolic hypertension is most effective in older patients with high-risk profile. Circulation. 2001;104(16):1923–1926.
  135. Fleig WE, Stange EF, Hunecke R, et al. Prevention of recurrent bleeding in cirrhotics with recent variceal hemorrhage: prospective, randomized comparison of propranolol and sclerotherapy. Hepatology. 1987;7(2):355–361.
  136. Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalalgia. 2001;21(1):61–65.
  137. Fletcher AE, Bulpitt CJ, Chase DM, et al. Quality of life with three antihypertensive treatments. Hypertension. 1992;19(6 Pt 1):499–507.
  138. Fletcher AE, Chester PC, Hawkins CM, Latham AN, Pike LA, Bulpitt CJ. The effects of verapamil and propranolol on quality of life in hypertension. J. Hum. Hypertens. 1989;3(2):125–130.
  139. Floris B, Paoletti G, Pelizza L, Bertulla A, Motolese M. A comparison of metoprolol OROS with antenolol in the treatment of effort angina pectoris: a randomized double-blind study. International Journal of Clinical Pharmacology, Therapy, & Toxicology. 1991;29(4):139–143.
  140. Foale RA. Atenolol versus the fixed combination of atenolol and nifedipine in stable angina pectoris. Eur. Heart J. 1993;14(10):1369–1374.
  141. Foerster EC, Greminger P, Siegenthaler W, Vetter H, Vetter W. Atenolol versus pindolol: side-effects in hypertension. Eur. J. Clin. Pharmacol. 1985;28(Suppl):89–91.
  142. Fogari R, Preti P, Derosa G, et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur. J. Clin. Pharmacol. 2002;58(3):177–180.
  143. Fogari R, Zoppi A, Corradi L, Mugellini A, Poletti L, Lusardi P. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am. J. Hypertens. 1998;11(10):1244–1247.
  144. Fogari R, Zoppi A, Corradi L, Preti P, Mugellini A, Lusardi P. Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J. Cardiovasc. Pharmacol. 1999;33(4):534–539.
  145. Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am. J. Hypertens. 2001;14(1):27–31.
  146. Fossum E, Moan A, Kjeldsen SE, et al. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. J. Am. Coll. Cardiol. Sep 6 2005;46(5):770–775.
  147. Fossum E, Olsen MH, Hoieggen A, et al. Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. Journal of Clinical Hypertension. Mar 2006;8(3):169–173.
  148. Fournier C, Brunet M, Bah M, et al. Comparison of the efficacy of propranolol and amiodarone in suppressing ventricular arrhythmias following myocardial infarction. Eur. Heart J. 1989;10(12):1090–1100.
  149. Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. Eur. Heart J. 1996;17(1):96–103.
  150. Franzen D, Metha A, Seifert N, Braun M, Hopp HW. Effects of beta-blockers on sexual performance in men with coronary heart disease. Int. J. Impot. Res. 2001;13(6):348–351.
  151. Freytag F, Schelling A, Meinicke T, Deichsel G, Telmisartan Hypertension Experience in a Randomized European Study Versus Atenolol Study G. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. Clin. Ther. 2001;23(1):108–123.
  152. Frick MH, Luurila O. Double-blind titrated-dose comparison of metoprolol and propranolol in the treatment of angina pectoris. Annals of Clinical Research. 1976;8(6):385–392.
  153. Frimodt-Moeller J, Poulsen DL, Kornerup HJ, Bech P. Quality of life, side effects and efficacy of lisinopril compared with metoprolol in patients with mild to moderate essential hypertension. J. Hum. Hypertens. 1991;5(3):215–221.
  154. Frishman W, Klein N, Strom J, et al. Double-blind randomized placebo controlled crossover comparison of propranolol and verapamil in patients with angina pectoris and systemic hypertension. Am. J. Cardiol. 1982;49(4II).
  155. Frishman WH, Klein NA, Klein P, et al. Comparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris. Am. J. Cardiol. 1982;50(5):1164–1172.
  156. Furberg CD, Black DM. The systolic hypertension in the elderly pilot program: methodological issues. Eur. Heart J. 1988;9(2):223–227.
  157. Furberg CD, Wright Jr JT, Davis BR, et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288(23):2981–2997.
  158. Galcera-Tomas J, Castillo-Soria FJ, Villegas-Garcia M, et al. Effects of early use of atenolol or captopril on infarct size and ventricular volume: A double-blind comparison in patients with anterior acute myocardial infarction. Circulation. 2001;103(6):813–819.
  159. Gawel MJ, Kreeft J, Nelson RF, Simard D, Arnott WS. Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can. J. Neurol. Sci. 1992;19(3):340–345.
  160. Gerber WD, Schellenberg R, Thom M, et al. Cyclandelate versus propranolol in the prophylaxis of migraine--a double-blind placebo-controlled study. Funct. Neurol. 1995;10(1):27–35.
  161. Glik DC, Steadman MS, Michels PJ, Mallin R. Antihypertensive regimen and quality of life in a disadvantaged population. J. Fam. Pract. 1990;30(2):143–149; discussion 150–142.
  162. Gonzalez Maqueda I. Adrenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol. Coron. Artery Dis. 1994;5(11):909–918.
  163. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis: Mortality and functional outcomes in the GUSTO- I trial. Circulation. 1995;92(10):2811–2818.
  164. Graff DW, Williamson KM, Pieper JA, et al. Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. J. Clin. Pharmacol. 2001;41(1):97–106.
  165. Grimm RH, Jr., Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Hypertension. 1997;29(1 Pt 1):8–14.
  166. Grossman E, Messerli FH, Goldbourt U. High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? Arch. Intern. Med. 2000;160(16):2447–2452.
  167. Grossman E, Messerli FH, Goldbourt U. Carcinogenicity of antihypertensive therapy. Current Hypertension Reports. 2002;4(3):195–201.
  168. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology. 1990;99(5):1401–1407.
  169. Guazzi M, Fiorentini C, Polese A, Magrini F, Olivari MT. Treatment of spontaneous angina pectoris with beta blocking agents. A clinical, electrocardiographic, and haemodynamic appraisal. Br Heart J. 1975;37(12):1235–1245.
  170. Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. Ann. Intern. Med. 1997;126(10):761–767.
  171. Gupta RC. Effect of oral proporanolol on the extent of acute anterior myocardial infarction [abstract]. Paper presented at: Ninth World Congress on Cardiology1982; Moscow.
  172. Gupta RC, Sharma SK, Arora YK, Tripathi K. Reduction of infarct size by early use of oral propranolol and verapamil in acute myocardial infarction. J. Assoc. Physicians India. 1985;33(9):577–580.
  173. Hackett GI, Harrison P, Kershaw S. Long-acting beta-blockers in the twenty-fourth hour. Practitioner. 1981;225(1355):752–755.
  174. Halperin AK, Gross KM, Rogers JF, Cubeddu LX. Verapamil and propranolol in essential hypertension. Clinical Pharmacology & Therapeutics. 1984;36(6):750–758.
  175. Hammon JW, Jr., Wood AJ, Prager RL, Wood M, Muirhead J, Bender HW, Jr. Perioperative beta blockade with propranolol: reduction in myocardial oxygen demands and incidence of atrial and ventricular arrhythmias. Ann. Thorac. Surg. 1984;38(4):363–367.
  176. Hansson L. Results of the STOP-Hypertension-2 trial. Blood Pressure Supplement. 2000;2:17–20.
  177. Hansson L, Dahlof B, Ekbom T, Lindholm L, Schersten B, Wester PO. Key learning from the STOP-hypertension study: An update on the progress of the ongoing Swedish study of antihypertensive treatment in the elderly. Cardiovascular Drugs & Therapy. 1253;4(SUPPL. 6):1253–1255.
  178. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356(9227):359–365.
  179. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354(9192):1751–1756.
  180. Harpey C, Coker S, Sellier P, Maccario J, Detry JM. Permutation distribution estimation applied to the comparison of the profile of the activity of two antianginal drugs. Fundamental & Clinical Pharmacology. 1996;10(2):151–155.
  181. Harston WE, Friesinger GC. Randomized double-blind study of pindolol in patients with stable angina pectoris. Am. Heart J. 1982;104(2 Pt 2):504–511.
  182. Hauf-Zachariou U, Blackwood RA, Gunawardena KA, O’Donnell JG, Garnham S, Pfarr E. Carvedilol versus verapamil in chronic stable angina: a multicentre trial. Eur. J. Clin. Pharmacol. 1997;52(2):95–100.
  183. Hauf-Zachariou U, Pfarr E, Van der Does R. Carvedilol in comparison and in combination with isosorbide dinitrate sustained release in patients with chronic stable effort-induced angina pectoris. Clinical Drug Investigation. 1997;14(6):465–473.
  184. Havanka-Kanniainen H, Hokkanen E, Myllyla VV. Long acting propranolol in the prophylaxis of migraine. Comparison of the daily doses of 80 mg and 160 mg. Headache. 1988;28(9):607–611.
  185. Havranek EP. The management of atrial fibrillation: Current perspectives. Am. Fam. Physician. 1994;50(5):959–968.
  186. Hawkins CM, Fletcher AE, Bulpitt CJ, Pike LA. The effects of verapamil and propranolol on quality of life in hypertension [abstract]. Br. J. Clin. Pharmacol. 1988;25(1).
  187. Hearing SD, Wesnes KA, Bowman CE. Beta blockers and cognitive function in elderly hypertensive patients: Withdrawal and consequences of ACE inhibitor substitution. International Journal of Geriatric Psychopharmacology. 1999;2(1):13–17.
  188. Hedman C, Winther K, Knudsen JB. The difference between non-selective and beta 1-selective beta-blockers in their effect on platelet function in migraine patients. Acta. Neurol. Scand. 1986;74(6):475–478.
  189. Held C, Hjemdahl P, Rehnqvist N, et al. Cardiovascular prognosis in relation to apolipoproteins and other lipid parameters in patients with stable angina pectoris treated with verapamil or metoprolol: results from the Angina Prognosis Study in Stockholm (APSIS). Atherosclerosis. 1997;135(1):109–118.
  190. Held C, Hjemdahl P, Rehnqvist N, et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Circulation. 1997;95(10):2380–2386.
  191. Helgeland A, Leren P. Oslo study: treatment of mild hypertension. Nephron. 1987;47(Suppl 1):108–110.
  192. Herlitz H, Jonsson O, Elmfeldt D, Naucler J, Berglund G. Intraerythrocyte sodium content and transmembrane sodium flux in hypertensive patients treated with diuretics or beta-adrenoceptorblockers. Acta Pharmacologica et Toxicologica. 1984;54(Suppl 1):37–42.
  193. Herner SJ, Seaton TL. Carvedilol following AMI. J. Fam. Pract. 1997;45(4):288–289.
  194. Hesse J, Mogelvang B, Simonsen H. Acupuncture versus metoprolol in migraine prophylaxis: a randomized trial of trigger point inactivation. J. Intern. Med. 1994;235(5):451–456.
  195. Hickey N, O’Donoghue S, Guiry U, et al. Metolazone and pindolol in the treatment of hypertension: a double blind multicentre trial. Ir. Med. J. 1982;75(6):194–196.
  196. Higgins SL, Daubert JL, Akhtar M, Cannom D. Who are the MADIT patients? Am. J. Cardiol. 1997;80(5 B):42F–46F.
  197. Hill JA, Gonzalez JI, Kolb R, Pepine CJ. Effects of atenolol alone, nifedipine alone and their combination on ambulant myocardial ischemia. Am. J. Cardiol. 1991;67(8):671–675.
  198. Hilleman DE, Ryschon KL, Mohiuddin SM, Wurdeman RL. Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation. J. Hum. Hypertens. 1999;13(7):477–483.
  199. Hillis WS, Tweddel AC, Murray RG, Lawrie TD. Comparative study of the effects of penbutolol and propranolol in the treatment of angina pectoris. Arzneimittelforschung. 1980;30(9):1595–1599.
  200. Holroyd KA, France JL, Cordingley GE, et al. Enhancing the effectiveness of relaxation-thermal biofeedback training with propranolol hydrochloride. Journal of Consulting & Clinical Psychology. 1995;63(2):327–330.
  201. Horvath JS, Caterson RJ, Collett P, Duggin GG, Kelly DH, Tiller DJ. Labetalol and bendrofluazide: comparison of their antihypertensive effects. Med. J. Aust. 1979;1(13):626–628.
  202. Hsu CY. Does treatment of non-malignant hypertension reduce the incidence of renal dysfunction? A meta-analysis of 10 randomised, controlled trials. J. Hum. Hypertens. 2001;15(2):99–106.
  203. Huang HL, Zhu S. [A comparison of effects between combination of nitroglycerin with metoprolol and nitroglycerin alone in patients with angina pectoris] [Chinese]. Guangdong Yixueyuan Xuebao. 2002;20(1):11–12.
  204. Hughes LO, Rose EL, Lahiri A, Raftery EB. Comparison of nicorandil and atenolol in stable angina pectoris. Am. J. Cardiol. 1990;66(7):679–682.
  205. Hung J, Lamb IH, Connolly SJ, Jutzy KR, Goris ML, Schroeder JS. The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: a double-blind, randomized, and placebo-controlled study. Circulation. 1983;68(3):560–567.
  206. Ideo G, Bellati G, Fesce E, Grimoldi D. Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study. Hepatology. 1988;8(1):6–9.
  207. Imai Y, Watanabe N, Hashimoto J, et al. Muscle cramps and elevated serum creatine phosphokinase levels induced by beta-adrenoceptor blockers. Eur. J. Clin. Pharmacol. 1995;48(1):29–34.
  208. Imperiale TF, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology. 2001;33(4):802–807.
  209. Ink O, Martin T, Poynard T, et al. Does elective sclerotherapy improve the efficacy of long-term propranolol for prevention of recurrent bleeding in patients with severe cirrhosis? A prospective multicenter, randomized trial. Hepatology. 1992;16(4):912–919.
  210. Insua JT, Sacks HS, Lau TS, et al. Drug treatment of hypertension in the elderly: A meta-analysis. Ann. Intern. Med. 1994;121(5):355–362.
  211. Jaattela A, Maki O. Comparison of long-acting propranolol and conventional metoprolol in the treatment of hypertension. Annals of Clinical Research. 1983;15(2):45–49.
  212. Jakobsen CJ, Bille S, Ahlburg P, Rybro L, Hjortholm K, Andresen EB. Perioperative metoprolol reduces the frequency of atrial fibrillation after thoracotomy for lung resection. Journal of Cardiothoracic & Vascular Anesthesia. 1997;11(6):746–751.
  213. James MA, Channer KS, Papouchado M, Rees JR. Improved control of atrial fibrillation with combined pindolol and digoxin therapy. Eur. Heart J. 1989;10(1):83–90.
  214. Jeng YS. Endoscopic injection sclerotherapy and propranolol in the prevention of recurrent variceal bleeding: A controlled randomized trial. Gastroenterol Endosc. 1989;31(3):611–619.
  215. Jenkins RM, Nagle RE. The symptomatic and objective effects of nifedipine in combination with beta-blocker therapy in severe angina pectoris. Postgrad. Med. J. 1982;58(685):697–700.
  216. Jern S, Hansson L, Schersten B, et al. Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. J. Cardiovasc. Pharmacol. 1991;18(Suppl 3):S7–8.
  217. Jiang X, Wang J, Chen S, Zhu C. A randomized controlled clinical trial in the prevention of esophageal variceal bleeding. Chinese Journal of Gastroenterology. 2001;6(2):90–93.
  218. Johnson SM, Mauritson DR, Corbett JR, Woodward W, Willerson JT, Hillis LD. Double-blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris. Am. J. Med. 1981;71(3):443–451.
  219. Kahler RL, Brill SJ, Perkins WE. The role of propranolol in the management of acute myocardial infarction. In: Kattus AA, Ross G, Hall YE, eds. Cardiovascular beta adrenergic responses. Los Angeles, CA: California Press; 1968:213–222.
  220. Kanadasi M, Demir M, Demirtas M, Akpinar O, Alhan CC. Effects of lisinopril, atenolol, and isosorbide 5-mononitrate on angina pectoris and QT dispersion in patients with syndrome X: An open-label, randomized, crossover study. Current Therapeutic Research, Clinical & Experimental. 2002;63(4):273–283.
  221. Karol MD, Locke CS, Cavanaugh JH. Lack of interaction between lansoprazole and propranolol, a pharmacokinetic and safety assessment. J. Clin. Pharmacol. 2000;40(3):301–308.
  222. Kaski JC, Rodriguez-Plaza L, Brown J, Maseri A. Efficacy of carvedilol in exercise-induced myocardial ischemia. J. Cardiovasc. Pharmacol. 1987;10(11).
  223. Kaul UA, Verma R, Garg KC. Early intervention with propranolol after acute myocardial infarction: serial left ventricular function determined by M-mode and cross-sectional echocardiography. Int. J. Cardiol. 1988;21(3):301–310.
  224. Kaushik R, Kaushik RM, Mahajan SK, Rajesh V. Biofeedback assisted diaphragmatic breathing and systematic relaxation versus propranolol in long term prophylaxis of migraine. Complement Ther Med. Sep 2005;13(3):165–174.
  225. Kawanishi DT, Reid CL, Morrison EC, Rahimtoola SH. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J. Am. Coll. Cardiol. 1992;19(2):409–417.
  226. Keller N, Sykulski R, Thamsborg G, Storm T, Larsen J. Atrial natriuretic peptide during exercise in patients with coronary heart disease before and after single dose atenolol and acebutolol. Acta Medica Scandinavica. 1988;223(4):305–311.
  227. Kirby PL, Caulfield MC, Collier DJ, et al. Differential response to amlodipine and atenolol mono-therapy for hypertension by ethnic group. J. Hum. Hypertens. 2001;15(SUPPL. 1):S61–S64.
  228. Kjaersgard Rasmussen MJ, Holt Larsen B, Borg L, Soelberg Sorensen P, Hansen PE. Tolfenamic acid versus propranolol in the prophylactic treatment of migraine. Acta. Neurol. Scand. 1994;89(6):446–450.
  229. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002;288(12):1491–1498.
  230. Kjeldsen SE, Dahlof B, Devereux RB, et al. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Am. J. Hypertens. 2000;13(8):899–906.
  231. Kjeldsen SE, Lyle PA, Kizer JR, et al. The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. Journal of Clinical Hypertension. Mar 2005;7(3):152–158.
  232. Klein G, Pfafferott C, Beil S, Gehring J, Niemela M, Kendall MJ. Effect of metoprolol and amlodipine on myocardial total ischaemic burden in patients with stable angina pectoris. Journal of Clinical Pharmacy & Therapeutics. 1997;22(5–6):371–378.
  233. Klein G, Scholze J. Efficacy and tolerability of 50 mg controlled release metoprolol (CR/Zok) once daily in comparison with conventional metoprolol 50 mg twice daily. Nieren-und Hochdruckkrankheiten. 1996;25(5):226–228.
  234. Klein WW, Jackson G, Tavazzi L. Efficacy of monotherapy compared with combined antianginal drugs in the treatment of chronic stable angina pectoris: A meta-analysis. Coronary Artery Disease. 2002;13(8):427–436.
  235. Koch G, Fransson L. Hemodynamic effects at rest and during exercise of combined alpha/beta-receptor blockade and of beta-receptor blockade alone in patients with ischemic heart disease. J. Cardiovasc. Pharmacol. 1987;10(4):474–478.
  236. Koch G, Fransson L. Hemodynamic and adrenergic effects of combined alpha/beta-receptor blockade versus combined beta-receptor and slow channel calcium blockade in patients with ischemic heart disease. Int. J. Cardiol. 1989;25(1):73–79.
  237. Kochiadakis GE, Kanoupakis EM, Kalebubas MD, et al. Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: A single-blinded crossover study. Europace. 2001;3(1):73–79.
  238. Kontopoulos AG, Athyros VG, Papageorgiou AA, Papadopoulos GV, Avramidis MJ, Boudoulas H. Effect of quinapril or metoprolol on heart rate variability in post-myocardial infarction patients. Am. J. Cardiol. 1996;77(4):242–246.
  239. Korula J, Groszmann RJ, Lerner E, Bosch J, Garcia-Tsao G, Grace ND. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage (2). Gastroenterology. 1991;101(2):590–592.
  240. Kostis JB. Comparison of the duration of action of atenolol and nadolol for treatment of angina pectoris. Am. J. Cardiol. 1988;62(17):1171–1175.
  241. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278(3):212–216.
  242. Kostis JB, Rosen RC, Brondolo E, Taska L, Smith DE, Wilson AC. Superiority of nonpharmacologic therapy compared to propranolol and placebo in men with mild hypertension: a randomized, prospective trial. Am. Heart J. 1992;123(2):466–474.
  243. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102(7):748–754.
  244. Laffer CL, Elijovich F. Essential hypertension of Caribbean hispanics: Sodium, renin, and response to therapy. Journal of Clinical Hypertension. 2002;4(4):266–273.
  245. Lagioia R, Scrutinio D, Ricci A, Ochan M, Rizzon P. Comparison of a fixed combination of nifedipine slow release and atenolol (BAY-R-1999) and nifedipine slow release alone in patients with stable angina pectoris: A multicenter, randomized, double-blind, parallel-group study. Current Therapeutic Research, Clinical & Experimental. 1995;56(11):1175–1184.
  246. Lai C, Onnis E, Pirisi R, Orani E, Delogu G, Cherchi A. Anti-ischaemic and anti-anginal activity of atenolol, nifedipine and their combination in stable, chronic effort angina. Drugs Under Experimental & Clinical Research. 1988;14(11):699–705.
  247. Lakshman MR, Reda DJ, Materson BJ, Cushman WC, Freis ED. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch. Intern. Med. 1999;159(6):551–558.
  248. Lamb RK, Prabhakar G, Thorpe JA, Smith S, Norton R, Dyde JA. The use of atenolol in the prevention of supraventricular arrhythmias following coronary artery surgery. Eur. Heart J. 1988;9(1):32–36.
  249. Lash JP, Wang X, Greene T, et al. Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2006;47(6):956–964.
  250. Lebrec D, Poynard T, Capron JP, et al. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomized trial. J. Hepatol. 1988;7(1):118–125.
  251. Ledwich JR. A trial of propranolol in myocardial infarction. Can. Med. Assoc. J. 1968;98(21):988–994.
  252. Lee DD, Kimura S, DeQuattro V. Noradrenergic activity and silent ischaemia in hypertensive patients with stable angina: effect of metoprolol. Lancet. 1989;1(8635):403–406.
  253. Legrand M, Krivitzky A. Antihypertensive effect of the fixed combination nifedipine sustained release 20 mg + atenolol 50 mg in partial responders to calcium channel blockers: Parthenon pilot study. Current Therapeutic Research, Clinical & Experimental. 1996;57(10):723–734.
  254. Leonetti G, Comerio G, Cuspidi C. Evaluating quality of life in hypertensive patients. Journal of Cardiovascular Pharmacology. 1994;23(SUPPL. 5):S54–S58.
  255. Leren P, Helgeland A. Oslo Hypertension Study. Drugs. 1986;31(Suppl 1):41–45.
  256. Levantesi D, Marraccini P, Michelassi C, Dalle Vacche M, L’Abbate A. Elective response to propranolol or verapamil in ischemia on effort. Can. J. Cardiol. 1989;5(6):299–304.
  257. Levine S, Croog SH, Sudilovsky A, Testa MA. Effects of antihypertensive medications on vitality and well-being. J. Fam. Pract. 1987;25(4):357–363.
  258. Lewis KA, Carbajal EV. ASPECT-2 study. Lancet. 2002;360(9350):2078; author reply 2078.
  259. Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J. Cardiovasc. Pharmacol. 1989;13(1):1–6.
  260. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):1004–1010.
  261. Lithell H, Selinus I, Hosie J, Frithz G, Weiner L. Efficacy and safety of bisoprolol and atenolol in patients with mild to moderate hypertension: a double-blind, parallel group international multicentre study. Eur. Heart J. 1987;8(Suppl M):55–64.
  262. Loaldi A, Montorsi P, Fabbiocchi F, et al. Angiographic evolution of coronary atherosclerosis in patients receiving propranolol. A two-year follow-up. Chest. 1991;99(5):1238–1242.
  263. Lopez NC, Corral JL, Rincon LA, et al. Nitrendipine and atenolol in essential hypertension in young and middle-aged patients: effect on serum lipids and left ventricular mass. J. Cardiovasc. Pharmacol. 1991;18(Suppl 1):S101–105.
  264. Loshak D. ASCOT: The race is on in hypertension. British Journal of Cardiology. 1997;4(5):179.
  265. Louis P, Schoenen J, Hedman C. Metoprolol versus clonidine in the prophylactic treatment of migraine. Cephalalgia. 1985;5(Suppl 3):520–521.
  266. Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin. Ther. 1997;19(4):730–742.
  267. Lucio Ede A, Flores A, Blacher C, Leaes PE, Lucchese FA, Ribeiro JP. Effectiveness of metoprolol in preventing atrial fibrillation and flutter in the postoperative period of coronary artery bypass graft surgery. Arq. Bras. Cardiol. 2004;82(1):42–46.
  268. Ludin, H P. A comparative trial with flunarizine and propranolol in migraine. Cephalalgia. 1987;7(Suppl 6):469–470.
  269. Lundell L, Leth R, Lind T, Lonroth H, Sjovall M, Olbe L. Evaluation of propranolol for prevention of recurrent bleeding from esophageal varices between sclerotherapy sessions. Acta Chirurgica Scandinavica. 1990;156(10):711–715.
  270. Luparini RL, Celli V, Piccirillo G, Guidi V, Cacciafesta M, Marigliano V. Carvedilol in elderly patients with chronic heart failure, a 12 weeks randomized, placebo controlled open trial. Archives of Gerontology & Geriatrics. 2000;29(3):275–282.
  271. Lustik SJ, Chhibber AK. Effects of atenolol on postoperative myocardial ischemia [5]. Anesthesiology. 1998;89(3):794–795.
  272. Maclean D. Aims of combination therapy--improved quality of life or better blood pressure control? Drugs. 1988;35(Suppl 4):16–21.
  273. Maltz MB, Dymond DS, Nathan AW, Camm AJ. A comparison of once daily bisoprolol, 5 and 10 mg, and atenolol 100 mg in the treatment of angina pectoris. Eur. Heart J. 1987;8(Suppl M):37–42.
  274. Manisalco MM, Newton W. Does a change to long-acting antianginals provide better symptom control, treatment satisfaction, and quality of life? J. Fam. Pract. 2001;50(11):991.
  275. Marbet UA, Straumann A, Gyr KE, et al. Reduction in early recurrence of variceal bleeding by propranolol. Scandinavian Journal of Gastroenterology. 1988;23(3):369–374.
  276. Marzilli M. Trimetazidine: A metabolic agent for the treatment of stable angina. European Heart Journal Supplements. 2001;3(O):012–015.
  277. Matangi MF, Strickland J, Garbe GJ, et al. Atenolol for the prevention of arrhythmias following coronary artery bypass grafting. Can. J. Cardiol. 1989;5(4):229–234.
  278. Mathew NT. Prophylaxis of migraine and mixed headache. A randomized controlled study. Headache. 1981;21(3):105–109.
  279. Mathur VS, Guinn GA. Prospective randomized study of coronary bypass surgery in stable angina. The first 100 patients. Circulation. 1975;52(2 Suppl).
  280. Mazur NA, Kulginskaya IV, Ivanova LA, et al. Results of long-term propranolol treatment in myocardial infarction survivors with advanced grades of ventricular extrasystoles. Cor et Vasa. 1984;26(4):241–247.
  281. McCorvey E, Jr., Wright JT, Jr., Culbert JP, McKenney JM, Proctor JD, Annett MP. Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients. Clinical Pharmacy. 1993;12(4):300–305.
  282. McKelvie R. Heart failure. Clinical Evidence. 2002(7):57–78.
  283. McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation. 2001;103(12):1644–1648.
  284. Merrick AF, Odom NJ, Keenan DJ, Grotte GJ. Comparison of propafenone to atenolol for the prophylaxis of postcardiotomy supraventricular tachyarrhythmias: a prospective trial. European Journal of Cardio Thoracic Surgery. 1995;9(3):146–149.
  285. Messerli FH, Grossman E. Hypertension in diabetes mellitus: role of beta-blockers. Drugs. 2001;61(10):1531–1533.
  286. Metcalfe MJ, Jennings K. A cross-over study comparing the efficacy of a combination of atenolol and nifedipine at different doses in angina pectoris. Current Medical Research & Opinion. 1995;13(5):251–256.
  287. Metelitsa VI, Douda SG, Ostrovskaya TP, et al. Long-term monotherapy with antihypertensives and quality of life in patients with mild to moderate arterial hypertension: A multicentre study. Journal of Drug Development & Clinical Practice. 1996;8(2):61–76.
  288. Metra M, Torp-Pedersen C, Swedberg K, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur. Heart J. 2005;26(21):2259–2268.
  289. Meyer FP. Meta-analysis of beta-blockers in heart failure. International Journal of Clinical Pharmacology & Therapeutics. 2001;39(12):561–563.
  290. Miall WE, Brennan PJ, Mann AH. Medical Research Council’s Treatment Trial for mild hypertension: an interim report. Clinical Science & Molecular Medicine - Supplement. 1976;3:563s–565s.
  291. Micieli G, Cavallini A, Marcheselli S, Mailland F, Ambrosoli L, Nappi G. Alpha-dihydroergocryptine and predictive factors in migraine prophylaxis. International Journal of Clinical Pharmacology & Therapeutics. 2001;39(4):144–151.
  292. Miller JL. Study documents benefits of beta-blockers in heart failure. Am. J. Health Syst. Pharm. 2000;57(8):729–730.
  293. Mills P, Garden OJ, Birnie GG, Carter DC. Propranolol in the prevention of further variceal haemorrhage in cirrhosis. Gastroenterology. 1987;92:1755.
  294. Mitrovic V, Miskovic A, Straub M, Thormann J, Pitschner H, Hamm C. Hemodynamic, antiischemic, and neurohumoral effects of tedisamil and atenolol in patients with coronary artery disease. Cardiovascular Drugs & Therapy. 2000;14(5):511–521.
  295. Mohr R, Smolinsky A, Goor DA. Prevention of supraventricular tachyarrhythmia with low-dose propranolol after coronary bypass. J Thorac. Cardiovasc. Surg. 1981;81(6):840–845.
  296. Morgan T, Adam W, Hodgson M. Adverse reactions to long-term diuretic therapy for hypertension. J. Cardiovasc. Pharmacol. 1984;6(Suppl 1):S269–273.
  297. Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am. J. Hypertens. 2001;14(3):241–247.
  298. Morrissette DL, Skinner MH, Hoffman BB, Levine RE, Davidson JM. Effects of antihypertensive drugs atenolol and nifedipine on sexual function in older men: a placebo-controlled, crossover study. Arch. Sex. Behav. 1993;22(2):99–109.
  299. Moser M, Lunn J. Comparative effects of pindolol and hydrochlorothiazide in black hypertensive patients. Angiology. 1981;32(8):561–566.
  300. Mulcahy D, Crake T, Crean P, Keegan J, Wright C, Fox KM. Therapeutic implications of dynamic coronary stenosis in patients with single vessel coronary artery disease. Eur. Heart J. 1991;12(4):514–519.
  301. Myers MG, Baigrie RS, Dubbin JD. Nifedipine versus propranolol treatment for unstable angina in the elderly. Can. J. Cardiol. 1988;4(8):402–406.
  302. Nager F, Favre H. Double-blind study with propranolol and LB-46 in angina pectoris. In: Kaltenbach ME, Lechten P, eds. Coronary heart disease. International symposium. Stutgart, Germany: George Thieme Verlag; 1971:224.
  303. Natale A, Newby KH, Pisano E, et al. Prospective randomized comparison of antiarrhythmic therapy versus first- line radiofrequency ablation in patients with atrial flutter. J. Am. Coll. Cardiol. 2000;35(7):1898–1904.
  304. Nestel PJ. Evaluation of propranolol (“Inderal”) in the treatment of angina pectoris. Med. J. Aust. 1966;2(27):1274–1276.
  305. Norton M. Metoprolol vs carvedilol in heart failure. Current Controlled Trials in Cardiovascular Medicine. 2000;1(3):175–176.
  306. Novo S, Abrignani MG, Novo G, et al. Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH. Am. J. Hypertens. 2001;14(7 Pt 1):637–643.
  307. Nyberg G, Bjuro T, Hagman M, Smith U. Relation between ST-depression and chest pain in patients with coronary heart disease receiving no treatment and after beta-blockade and combined alpha-beta-blockade. Acta Medica Scandinavica Supplementum. 1981;644:30–33.
  308. O’Connor KW, Lehman G, Yune H, et al. Comparison of three nonsurgical treatments for bleeding esophageal varices. Gastroenterology. 1989;96(3):899–906.
  309. Ogawa H, Yasue H, Nakamura N, Fujii H, Miyagi H, Kikuta K. Comparison of efficacy of nisoldipine, metoprolol, and isosorbide dinitrate in patients with stable exertional angina: A randomized, cross-over, placebo-controlled study. International Journal of Cardiology. 1995;48(2):131–137.
  310. Ohtsuka T, Hamada M, Saeki H, et al. Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am. J. Cardiol. 2002;89(8):996–999.
  311. Olofsson BO, Nyhlin H, Wester PO. Beta-blockade or inhibition of angiotensin converting-enzyme does not affect intracellular magnesium or potassium. Current Therapeutic Research, Clinical & Experimental. 1989;46(1):121–125.
  312. Olsson G, Tuomilehto J, Berglund G, et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Am. J. Hypertens. 1991;4(2 Pt 1):151–158.
  313. Omvik P, Lund-Johansen P, Haugland H. Modest antihypertensive effect of epanolol, a beta 1-selective receptor blocker with beta 1 agonist activity: an acute and long-term hemodynamic study at rest and during exercise and double crossover comparison with atenolol on ambulatory blood pressure. Cardiovascular Drugs & Therapy. 1993;7(1):125–132.
  314. Ormerod OJ, McGregor CG, Stone DL, Wisbey C, Petch MC. Arrhythmias after coronary bypass surgery. Br Heart J. 1984;51(6):618–621.
  315. Ostergren J, Storstein L, Karlberg BE, Tibblin G. Quality of life in hypertensive patients treated with either carvedilol or enalapril. Blood Press. 1996;5(1):41–49.
  316. Pagliaro L. Lebrec D, Poynard T, Hillon P, Benhamou J-P. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. A controlled study [N Engl J Med 1981;305:1371–1374]. J. Hepatol. 2002;36(2):148–150.
  317. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet. 2000;356(9246):1949–1954.
  318. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care. 2000;23(7):888–892.
  319. Pahor M, Shorr RI, Somes GW, et al. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program. Arch. Intern. Med. 1998;158(12):1340–1345.
  320. Palmer AJ, Fletcher AE, Rudge PJ, Andrews CD, Callaghan TS, Bulpitt CJ. Quality of life in hypertensives treated with atenolol or captopril: a double-blind crossover trial. J. Hypertens. 1992;10(11):1409–1416.
  321. Papademetriou V, Narayan P, Kokkinos P. Effects of diltiazem, metoprolol, enalapril and hydrochlorothiazide on frequency of ventricular premature complexes. Am. J. Cardiol. 1994;73(4):242–246.
  322. Paran E, Anson O, Neumann L. The effects of replacing beta-blockers with an angiotensin converting enzyme inhibitor on the quality of life of hypertensive patients. Am. J. Hypertens. 1996;9(12 Pt 1):1206–1213.
  323. Parikka H, Toivonen L, Heikkila L, Virtanen K, Jarvinen A. Comparison of sotalol and metoprolol in the prevention of atrial fibrillation after coronary artery bypass surgery. J. Cardiovasc. Pharmacol. 1998;31(1):67–73.
  324. Parodi, O, Simonetti, et al. Verapamil versus propranolol for angina at rest. Am. J. Cardiol. 1982;50(4):923–928.
  325. Pasta L, Pagliaro L, SImonetti R, Maringhini A, Marceno M, al. e. Propranolol for prevention of upper GI rebleeding in cirrhosis. Ital. J. Gastroenterol. 1985;17:136–138.
  326. Paull DL, Tidwell SL, Guyton SW, et al. Beta blockade to prevent atrial dysrhythmias following coronary bypass surgery. Am. J. Surg. 1997;173(5):419–421.
  327. Peart WS. The problems of morbidity and therapy in borderline hypertension. Schweizerische Medizinische Wochenschrift Journal Suisse de Medecine. 1976;106(49):1706–1711.
  328. Penzien DB, Holroyd K, Cordingley G, Wagner M, Jackson B. Propranolol in the treatment of migraine headache: a meta-analytic review of the research literature. Headache. 1988;28:307–308.
  329. Perez V, Puiigdemont D, Gilaberte I, Alvarez E, Artigas F, Grup de Recerca en Trastorns A. Augmentation of fluoxetine’s antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. J. Clin. Psychopharmacol. 2001;21(1):36–45.
  330. Perry HM, Jr., Hall WD, Benz JR, et al. Efficacy and safety of atenolol, enalapril, and isradipine in elderly hypertensive women. Am. J. Med. 1994;96(1):77–86.
  331. Persson H, Eriksson SV, Erhardt L. Effects of beta receptor antagonists on left ventricular function in patients with clinical evidence of heart failure after myocardial infarction. A double-blind comparison of metoprolol and xamoterol. European Heart Journal. 1996;17(5):741–749.
  332. Persson H, Rythe’n-Alder E, Melcher A, Erhardt L. Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol. Br Heart J. 1995;74(2):140–148.
  333. Peter T, Norris RM, Clarke ED, et al. Reduction of enzyme levels by propranolol after acute myocardial infarction. Circulation. 1978;57:1091–1095.
  334. Philip IG, Qureshi SM, Richards HH, et al. A comparison of a hydrochlorothiazide plus triamterene combination (Dyazide) and atenolol in the treatment of patients with mild hypertension: a multicentre study in general practice. Br. J. Clin. Pract. 1987;41(10):947–953.
  335. Pomier-Layrargues G, Villeneuve JP, Willems B, Huet PM, Marleau D. Systemic and hepatic hemodynamics after variceal hemorrhage: effects of propranolol and placebo. Gastroenterology. 1987;93(6):1218–1224.
  336. Portegies MCM, Brouwer J, Van de Ven LLM, Viersma JW, Lie KI. Effects of bisoprolol and isosorbide dinitrate on the circadian distribution of myocardial ischemia. Current Therapeutic Research, Clinical & Experimental. 1995;56(12):1225–1236.
  337. Potempa K, Babich K, Fruh S, Fogg L. Blood pressure and mood responses in hypertensive patients on antihypertensive medications. Journal of the American Academy of Nurse Practitioners. 1993;5(5):211–218.
  338. Poulter NR. Managing the diabetic hypertensive patient. Journal of Diabetes & its Complications. 1996;10(3):141–143.
  339. Poulter NR, Sanderson JE, Thompson AV, Sever PS, Chang CL. Comparison of nifedipine and propranolol as second line agent for hypertension in black Kenyans. BMJ. 1993;306(6878):621–622.
  340. Prisant LM, Neutel JM, Ferdinand K, et al. Low-dose combination therapy as first-line hypertension treatment for blacks and nonblacks. J. Natl. Med. Assoc. 1999;91(1):40–48.
  341. Probstfield JL, Applegate WB, Borhani NO, et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. Clinical & Experimental Hypertension - Part A, Theory & Practice. 1989;11(5–6):973–989.
  342. Puljevic D, Smalcelj A, Durakovic Z, Goldner V. The influence of atenolol and propafenone on QT interval dispersion in patients 3 months after myocardial infarction. International Journal of Clinical Pharmacology & Therapeutics. 1997;35(9):381–384.
  343. Quyyumi AA, Wright C, Mockus L, Fox KM. Effect of partial agonist activity in beta blockers in severe angina pectoris: a double blind comparison of pindolol and atenolol. British Medical Journal Clinical Research Edition. 1984;289(6450):951–953.
  344. Rabkin R, Stables DP, Levin NW, Suzman MM. The prophylactic value of propranolol in angina pectoris. Am. J. Cardiol. 1966;18(3):370–383.
  345. Radevski IV, Valtchanova SP, Candy GP, Tshele EF, Sareli P. Comparison of acebutolol with and without hydrochlorothiazide versus carvedilol with and without hydrochlorothiazide in black patients with mild to moderate systemic hypertension. Am. J. Cardiol. 1999;84(1):70–75.
  346. Raftery EB. Calcium blockers and beta blockers: alone and in combination. Acta Medica Scandinavica Supplementum. 1985;694:188–196.
  347. Raftery EB, Lahiri A, Hughes LO, Rose EL. A double-blind comparison of a beta-blocker and a potassium channel opener in exercise induced angina. Eur. Heart J. 1993;14:35–39.
  348. Rainwater J, Steele P, Kirch D, LeFree M, Jensen D, Vogel R. Effect of propranolol on myocardial perfusion images and exercise ejection fraction in men with coronary artery disease. Circulation. 1982;65(1):77–81.
  349. Ray SG, McCann G, Henderson E, et al. Cardiorespiratory and symptomatic variables during maximal and submaximal exercise in men with stable effort angina: A comparison of atenolol and celiprolol. European Heart Journal. 1994;15(11):1566–1570.
  350. Rees-Jones DI, Oliver IM. A comparison of the antianginal efficacy of nifedipine alone and the fixed combination of atenolol and nifedipine. British Journal of Clinical Practice. 1994;48(4):174–177.
  351. Refsgaard J, Thomsen C, Andreasen F, Gotzsche O. Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure. European Journal of Heart Failure. 2002;4(4):445–453.
  352. Rehnqvist N, Billing E, Bjorkander I, et al. Ventricular arrhythmias and other base-line data in 790 patients followed for angina pectoris. Prognostic value and therapeutic implications. Report from APSIS. New Trends Arrhythmias. 1993;9(4):1169–1173.
  353. Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. Eur. Heart J. 1996;17(1):76–81.
  354. Rey E, LeLorier J, Burgess E, Lange IR, Leduc L. Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. Can Med Assoc J. 1997;157(9):1245–1254.
  355. Riedinger MS, Dracup KA, Brecht ML, Padilla G, Sarna L, Ganz PA. Quality of life in patients with heart failure: do gender differences exist? Heart & Lung: Journal of Acute & Critical Care. 2001;30(2):105–116.
  356. Romano M, Di Maro T, Carella G, et al. Atenolol and/or nifedipine in effort angina: which is the treatment of choice for exercise coronary protection? International Journal of Clinical Pharmacology, Therapy, & Toxicology. 1988;26(9):468–470.
  357. Rommel T, Demisch L. Influence of chronic beta-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension. Journal of Neural Transmission - General Section. 1994;95(1):39–48.
  358. Rosen JA. Observations on the efficacy of propranolol for the prophylaxis of migraine. Ann. Neurol. 1983;13(1):92–93.
  359. Rosen RC, Kostis JB, Jekelis A, Taska LS. Sexual sequelae of antihypertensive drugs: treatment effects on self-report and physiological measures in middle-aged male hypertensives. Arch. Sex. Behav. 1994;23(2):135–152.
  360. Rosenthal J, Bahrmann H, Benkert K, et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta-blocker. Cardiology. 1996;87(5):409–414.
  361. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am. J. Cardiol. Feb 1 2005;95(3):311–316.
  362. Russell ROJ, Moraski RE, Kouchoukos N, et al. Unstable angina pectoris: National cooperative study group to compare surgical and medical therapy. II. In-hospital experience and initial follow-up results in patients with one, two and three vessel disease. Am. J. Cardiol. 1978;42(5):839–848.
  363. Ryan R. Comparative study of nadolol and propranolol in prophylactic treatment of migraine. Am. Heart J. 1984;108(4II):1156–1159.
  364. Ryden L, Malmberg K. Calcium channel blockers or beta receptor antagonists for patients with ischaemic heart disease. Eur. Heart J. 1996;17(1):1–3.
  365. Santucci A, Puccetti F, Ficara C, et al. Angiotensin converting enzyme inhibition and quality of life: A randomized controlled trial. Current Therapeutic Research, Clinical & Experimental. 1989;46(5):849–857.
  366. Saran RK, Bhandari K, Narain VS, et al. Intravenous streptokinase in the management of a subset of patients with unstable angina: a randomized controlled trial. Int. J. Cardiol. 1990;28(2):209–213.
  367. Sarin SK, Lamba GS, Kumar M, Misra A, Murthy NS. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N. Engl. J. Med. 1999;340(13):988–993.
  368. Sarin SK, Wadhawan M, Gupta R, Shahi H. Evaluation of endoscopic variceal ligation (EVL) versus propanolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirrhotic patients. Digestive Diseases & Sciences. Aug 2005;50(8):1538–1547.
  369. Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. J. Am. Coll. Cardiol. 1996;27(2):311–316.
  370. Schang SJ, Jr., Pepine CJ. Transient asymptomatic S-T segment depression during daily activity. Am. J. Cardiol. 1977;39(3):396–402.
  371. Schnellbacher K, Bestehorn HP, Roskamm H. Hemodynamics and exercise tolerance after bisoprolol, nifedipine, and their combination in patients with angina pectoris. J. Cardiovasc. Pharmacol. 1990;16(Suppl 5):S201–207.
  372. Scholze J, Klein G. Equivalent blood pressure reduction and tolerability with controlled-release metoprolol 50 mg once daily and conventional metoprolol 50 mg twice daily. A double-blind 8-week comparison in hypertensive patients. Clinical Drug Investigation. 1996;11(6):331–338.
  373. Schurmans J, Piessens J, Kesteloot H, De Geest H. Comparative effects of alinidine and propranolol in ischaemic heart disease. Eur. J. Clin. Pharmacol. 1982;23(5):389–396.
  374. Seidl K, Hauer B, Schwick NG, Zahn R, Senges J. Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator. Am. J. Cardiol. 1998;82(6):744–748.
  375. Senior R, Muller-Beckmann B, DasGupta P, van der Does R, Lahiri A. Effects of carvedilol on ventricular arrhythmias. J. Cardiovasc. Pharmacol. 1992;19(1).
  376. Shapiro W, Narahara KA, Kostis JB, Thandroyen F, Zohman LR. Comparison of atenolol and nifedipine in chronic stable angina pectoris. Am. J. Cardiol. 1989;64(3):186–190.
  377. Shimell CJ, Fritz VU, Levien SL. A comparative trial of flunarizine and propranolol in the prevention of migraine. S. Afr. Med. J. 1990;77(2):75–77.
  378. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA. 1997;278(1):40–43.
  379. Sica DA, Weber M. The Losartan Intervention for Endpoint Reduction (LIFE) trial-have angiotensin-receptor blockers come of age? Journal of Clinical Hypertension. 2002;4(4):301–305.
  380. Simarro E, Rodriguez MA, Bayon J, et al. Effect of gallopamil and propranolol in patients with coronary heart disease and moderately depressed left ventricular ejection fraction. Rev. Esp. Cardiol. 1995;48(11):741–745.
  381. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am. J. Med. 2002;113(8):650–656.
  382. Singh N, Mironov D, Goodman S, Morgan CD, Langer A. Treatment of silent ischemia in unstable angina: A randomized comparison of sustained-release verapamil versus metoprolol. Clinical Cardiology. 1995;18(11):653–658.
  383. Sloman G, Stannard M. Beta-adrenergic blockade and cardiac arrhythmias. Br. Med. J. 1967;4(578):508–512.
  384. Sogaard, P E. Propranolol in portal hypertension [letter]. Lancet. 1981;1(8231).
  385. Sorensen, P S. Prophylactic effects of flunarizine versus metoprolol in migraine. Cephalalgia. 1989;9(Suppl 10):355–356.
  386. Sorensen PS, Larsen BH, Rasmussen MJ, et al. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache. 1991;31(10):650–657.
  387. Soyka D, Oestreich W. Therapeutic effectiveness of flunarizine and propranolol in the interval therapy of migraine. Cephalalgia. 1987;7(suppl 6):467–468.
  388. Steeds RP, Birchall AS, Smith M, Channer KS. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart. 1999;82(2):170–175.
  389. Steffensen R, Grande P, Pedersen F, Haunso S. Effects of atenolol and diltiazem on exercise tolerance and ambulatory ischaemia. Int. J. Cardiol. 1993;40(2):143–153.
  390. Steinbeck G, Greene HL. Management of patients with life-threatening sustained ventricular tachyarrhythmias - The role of guided antiarrhythmic drug therapy. Progress in Cardiovascular Diseases. 1996;38(6):419–428.
  391. Steiner SS, Friedhoff AJ, Wilson BL, Wecker JR, Santo JP. Antihypertensive therapy and quality of life: a comparison of atenolol, captopril, enalapril and propranolol. J. Hum. Hypertens. 1990;4(3):217–225.
  392. Stensrud P, Sjaastad O. Short-term clinical trial of phopranolol in racemic form (Inderal), D-propranolol and placebo in migraine. Acta. Neurol. Scand. 1976;53(3):229–232.
  393. Stephenson LW, MacVaugh HI, Tomasello DN, Josephson ME. Propranolol for prevention of postoperative cardiac arrhythmias: A randomized study. Ann. Thorac. Surg. 1980;29(2):113–116.
  394. Stewart KJ, Kelemen MH, Ewart CK. Relationships between self-efficacy and mood before and after exercise training. Journal of Cardiopulmonary Rehabilitation. 1994;14(1):35–42.
  395. Stone PH, Gibson RS, Glasser SP, et al. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. The ASIS Study Group. Circulation. 1990;82(6):1962–1972.
  396. Storstein L. Effect of intravenous and oral pindolol on exercise tolerance and electrocardiographic changes in angina pectoris. J. Cardiovasc. Pharmacol. 1980;2(6):739–750.
  397. Straat E, Edlund A, Henriksson P. Improved working capacity in patients with ischaemic heart disease during a 10-day treatment with oral theophylline. J. Intern. Med. 1992;232(1):53–58.
  398. Sudilovsky, A, Stern, M, Meyer, J H. Comparative efficacy of nadolol and propranolol in the prophylaxis of migraine. Headache. 1986;26(6):311–312.
  399. Sudilovsky A, Elkind AH, Ryan RES, et al. Comparative efficacy of nadolol and propranolol in the management of migraine. Headache. 1987;27(8):421–426.
  400. Suwa M, Ito T, Otake Y, Moriguchi A, Hirota Y, Kawamura K. Comparison of the therapeutic effects of the beta-blocking agent bisoprolol and the calcium-blocking agent diltiazem in patients with heart failure due to dilated cardiomyopathy. Jpn. Circ. J. 1996;60(10):767–773.
  401. Tangeman HJ, Patterson JH. Extended-release metoprolol succinate in chronic heart failure. Ann. Pharmacother. 2003;37(5):701–710.
  402. Tatli E, Kurum T. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. Can. J. Cardiol. Mar 15 2005;21(4):344–348.
  403. Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet. 1981;1(8232):1225–1228.
  404. Tepper D. Multicenter oral carvedilol heart failure assessment (MOCHA): A six-month dose-response evaluation in class II–IV patients: Comment. Prevention and Management of Congestive Heart Failure. 1996;2(1):39–40.
  405. Tepper D. Carvedilol inhibits clinical progression in patients with mild heart failure: Comment. Prevention and Management of Congestive Heart Failure. 1996;2(1).
  406. Testa MA, Hollenberg NK, Anderson RB, Williams GH. Assessment of quality of life by patient and spouse during antihypertensive therapy with atenolol and nifedipine gastrointestinal therapeutic system. Am. J. Hypertens. 1991;4(4 Pt 1):363–373.
  407. Theroux P, Taeymans Y, Morissette D, Bosch X, Pelletier GB, Waters DD. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. J. Am. Coll. Cardiol. 1985;5(3):717–722.
  408. Thorpe P. Pindolol (Visken) and angina pectoris: a double blind multicentre trial. N. Z. Med. J. 1972;76(484):171–173.
  409. Thuluvath PJ, Krishnan A. Primary prophylaxis of variceal bleeding. Gastrointest. Endosc. 2003;58(4):558–567.
  410. Tijssen JG, Lubsen J. Nifedipine and metoprolol in unstable angina: findings from the Holland Interuniversity Nifedipine/Metoprolol Trial (HINT). J. Cardiovasc. Pharmacol. 1987;10(Suppl 2):S15–22; discussion S23–14.
  411. Tolg R, Witt M, Schwarz B, et al. Comparison of carvedilol and metoprolol in patients with acute myocardial infarction undergoing primary coronary intervention--the PASSAT Study. Clinical research in cardiology : official journal of the German Cardiac Society. 2006;95(1):31–41.
  412. Tuomilehto J, Wikstrand J, Olsson G, et al. Decreased coronary heart disease in hypertensive smokers. Hypertension. 1989;13(6 Pt 2):773–780.
  413. Tuomilehto J, Wikstrand J, Warnold I, Olsson G, Elmfeldt D, Berglund G. Coronary artery disease can be prevented by antihypertensive therapy: experiences from the MAPHY Study. J. Cardiovasc. Pharmacol. 1990;16(Suppl 7):S75–76.
  414. Tzivoni D, Medina A, David D, Barzilai Y, Brunel P. Effect of metoprolol in reducing myocardial ischemic threshold during exercise and during daily activity. Am. J. Cardiol. 1998;81(6):775–777.
  415. Urbistondo M, Torres EA, Castro F, et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. P. R. Health Sci. J. 1996;15(3):195–199.
  416. Uribe M, Ballesteros A, Strauss R, Rosales J, Guevera L. Use of cardioselective beta blockers in portal hypertension and advanced liver disease. Gastroenterology. 1983;84:1339.
  417. Vaccarino V, Berger AK, Abramson J, et al. Pulse pressure and risk of cardiovascular events in the systolic hypertension in the elderly program. Am. J. Cardiol. 2001;88(9):980–986.
  418. Van de Ven LLM, Vermeulen A, Tans JGM, et al. Which drug to choose for stable angina pectoris: A comparative study between bisoprolol and nitrates. Int. J. Cardiol. 1995;47(3):217–223.
  419. Van de Werf F, Janssens L, Brzostek T, et al. Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy. J. Am. Coll. Cardiol. 1993;22(2):407–416.
  420. Vanmolkot FH, de Hoon JN, van de Ven LL, Van Bortel LM. Impact of antihypertensive treatment on quality of life: comparison between bisoprolol and bendrofluazide. J. Hum. Hypertens. 1999;13(8):559–563.
  421. Verspeelt J, De Locht P, Amery WK. Postmarketing study of the use of flunarizine in vestibular vertigo and in migraine. Eur. J. Clin. Pharmacol. 1996;51(1):15–22.
  422. Verspeelt J, De Locht P, Amery WK. Post-marketing cohort study comparing the safety and efficacy of flunarizine and propranolol in the prophylaxis of migraine. Cephalalgia. 1996;16(5):328–336; discussion 288.
  423. Vickers C, Rhodes J, Hillenbrand P, Bradby H, Hawker P, al. e. Prospective controlled trial of propranolol and sclerotherapy for prevention of rebleeding from oesophageal varices. Gut. 1987;28:A1359.
  424. Von Arnim T. Prognostic significance of transient ischemic episodes: Response to treatment shows improved prognosis: Results of the total ischemic burden bisoprolol study (TIBBS) follow-up. Journal of the American College of Cardiology. 1996;28(1):20–24.
  425. Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J. Am. Coll. Cardiol. Mar 1 2005;45(5):705–711.
  426. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J. Am. Coll. Cardiol. Mar 1 2005;45(5):712–719.
  427. Wallace A, Layug B, Tateo I, et al. Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. Anesthesiology. 1998;88(1):7–17.
  428. Wallace WA, Wellington KL, Chess MA, Liang CS. Comparison of nifedipine gastrointestinal therapeutic system and atenolol on antianginal efficacies and exercise hemodynamic responses in stable angina pectoris. Am. J. Cardiol. 1994;73(1):23–28.
  429. Wallen NH, Held C, Rehnqvist N, Hjemdahl P. Platelet aggregability in vivo is attenuated by verapamil but not by metoprolol in patients with stable angina pectoris. American Journal of Cardiology. 1995;75(1):1–6.
  430. Wallis DE, Pope C, Littman WJ, Scanlon PJ. Safety and efficacy of esmolol for unstable angina pectoris. Am. J. Cardiol. 1988;62(16):1033–1037.
  431. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Preventive effects of carvedilol on nitrate tolerance--a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol. J. Am. Coll. Cardiol. 1998;32(5):1201–1206.
  432. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. J. Am. Coll. Cardiol. 1998;32(5):1194–1200.
  433. Weir MR, Josselson J, Ekelund LG, et al. Nicardipine as antihypertensive monotherapy: positive effects on quality of life. J. Hum. Hypertens. 1991;5(3):205–213.
  434. Weir MR, Prisant LM, Papademetriou V, et al. Antihypertensive therapy and quality of life. Am. J. Hypertens. 1996;9(9):854–859.
  435. Wendt T. Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease. Clinical Investigator. 1992;70(Suppl 1):S93–97.
  436. Wendt T, van der Does R, Schrader R, Landgraf H, Kober G. Acute hemodynamic effects of the vasodilating and beta-blocking agent carvedilol in comparison to propranolol. J. Cardiovasc. Pharmacol. 1987;10(Suppl 11):S147–150.
  437. Westaby D, Melia W, Hegarty J, Gimson AE, Stellon AJ, Williams R. Use of propranolol to reduce the rebleeding rate during injection sclerotherapy prior to variceal obliteration. Hepatology. 1986;6(4):673–675.
  438. Westaby D, Melia WM, Macdougall BR, Hegarty JE, Gimson AE, Williams R. B1 selective adrenoreceptor blockade for the long term management of variceal bleeding. Gut. 1985;26(4):421–425.
  439. Westaby D, Polson R, Gimson A, Hayes P, Williams R. Comparison of propranolol with injection sclerotherapy in prevention of rebleeding from oesophageal varices in cirrhotic patients. Drugs. 1989;37(Suppl 2):42–46; discussion 47.
  440. Westaby D, Polson RJ, Gimson AE, Hayes PC, Hayllar K, Williams R. A controlled trial of oral propranolol compared with injection sclerotherapy for the long-term management of variceal bleeding. Hepatology. 1990;11(3):353–359.
  441. Wikstrand J. Primary prevention in patients with hypertension: comments on the clinical implications of the MAPHY Study. Metoprolol Atherosclerosis Prevention in Hypertensives Study. Am. Heart J. 1988;116(1 Pt 2):338–347.
  442. Wikstrand J. Primary prevention with beta-blockade in patients with hypertension: Review of results and clinical implications. J. Cardiovasc. Pharmacol. 1990;16(SUPPL. 5):S64–S75.
  443. Wikstrand J, Warnold I, Tuomilehto J, et al. Metoprolol versus thiazide diuretics in hypertension. Hypertension. 1991;17(4):579–588.
  444. Williams GH, Croog SH, Levine S, Testa MA, Sudilovsky A. Impact of antihypertensive therapy on quality of life: effect of hydrochlorothiazide. Journal of Hypertension - Supplement. 1987;5(1):S29–35.
  445. Willich SN, Pohjola-Sintonen S, Bhatia SJ, et al. Suppression of silent ischemia by metoprolol without alteration of morning increase of platelet aggregability in patients with stable coronary artery disease. Circulation. 1989;79(3):557–565.
  446. Winniford MD, Huxley RL, Hillis LD. Randomized, double-blind comparison of propranolol alone and a propranolol-verapamil combination in patients wuth severe angina of effort. J. Am. Coll. Cardiol. 1983;1(2I):492–498.
  447. Wright RA, Perrie AM, Stenhouse F, et al. The long-term effects of metoprolol and epanolol on tissue-type plasminogen activator and plasminogen activator inhibitor 1 in patients with ischaemic heart disease. European Journal of Clinical Pharmacology. 1994;46(3):279–282.
  448. Xie MR, Yang LP, Zhuang HZ, and, et al. The Effect of Cedilanid and Metoprolol in Controlling the Ventricular Rate of the Patients with Fast Atrial Fibrillation. Chinese Journal of Medical Guide. 2000;2(6):22–23.
  449. Yazicioglu L, Eryilmaz S, Sirlak M, et al. The effect of preoperative digitalis and atenolol combination on postoperative atrial fibrillation incidence. European Journal of Cardio-Thoracic Surgery. 2002;22(3):397–401.
  450. Yoshikawa T, Baba A, Suzuki M, et al. Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. Am. J. Cardiol. 2000;85(12):1495–1497; A1497.
  451. Yu WC, Chen SA, Lee SH, et al. Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs. Circulation. 1998;97(23):2331–2337.
  452. Yusuf S, Ramsdale D, Peto R, et al. Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial. Lancet. 1980;2(8189):273–276.
  453. Zachariah PK, Brobyn R, Kann J, et al. Comparison of quality of life on nitrendipine and propranolol. J. Cardiovasc. Pharmacol. 1988;12(Suppl 4):S29–35.
  454. Zanchetti A, Bond MG, Hennig M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002;106(19):2422–2427.
Copyright © 2009, Oregon Health & Science University, Portland, Oregon.
Cover of Drug Class Review: Beta Adrenergic Blockers
Drug Class Review: Beta Adrenergic Blockers: Final Report Update 4 [Internet].
Helfand M, Peterson K, Christensen V, et al.
Portland (OR): Oregon Health & Science University; 2009 Jul.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...